To learn about our parent company, Takeda Pharmaceutical Company Limited, please visit http://www.takeda.com/
Please contact us at US.firstname.lastname@example.org or (224) 554-5499.
Takeda Receives Complete Response Letter from U.S. FDA for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis
Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool to Redefine Crohn’s Disease Management
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019
Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting
First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes: Takeda’s Investigational Therapy Meets Co-Primary & Key Secondary Efficacy Endpoints
SEE ALL NEWS AND RELEASES >
Copyright 2019 Takeda Pharmaceutical Company Limited. All rights reserved.Certified Top Employer
You are about to leave www.Takeda.com/en-us and be redirected to another Takeda domain.